GeoVax Labs, Inc. — Q2 2013 Form 10-Q
Reporting period: Three and six months ended June 30, 2013; unaudited. GeoVax is a development-stage biotechnology company developing HIV vaccines, with candidates in human clinical trials. It had no approved products or product sales; revenue consisted of NIH grant funding.
Financial results and liquidity
| Metric | Q2 2013 | Q2 2012 | Six months 2013 | Six months 2012 |
|---|---|---|---|---|
| Grant revenue | $441,561 | $705,698 | $1,238,601 | $1,559,761 |
| Research and development | $553,199 | $712,416 | $1,435,187 | $1,784,770 |
| General and administrative | $415,784 | $492,316 | $1,028,727 | $1,005,134 |
| Operating loss | $(527,422) | $(499,034) | $(1,225,313) | $(1,230,143) |
| Net loss | $(526,284) | $(497,763) | $(1,223,081) | $(1,228,276) |
| Loss per share | $(0.02) | $(0.03) | $(0.06) | $(0.07) |
- At June 30, cash and cash equivalents were $1.88 million, versus $1.04 million at year-end 2012. Working capital was $1.79 million; total assets were $2.04 million.
- Six-month operating cash use was $797,866, compared with $1.66 million in the first half of 2012. Financing provided $1.64 million, primarily from warrant exercises; cash increased by $845,468.
- Current liabilities were $151,613. The company reported no long-term debt, committed credit line, or other committed funding.
- Accumulated deficit was approximately $26.0 million. Profit margins are not a meaningful indicator given the company’s grant-funded, pre-commercial operations.
Changes and unusual items
- First-half grant revenue fell 21% year over year, reflecting the timing of grant-funded expenditures. R&D expense declined 20%; reported net loss was nearly unchanged.
- Q2 net loss increased about 6% year over year despite lower grant revenue and operating expenses.
- First-half G&A included $238,168 of expense related to repricing and extending Series B warrants. The company reduced warrant exercise prices, and holders exercised 2,933,333 warrants for total proceeds of $1,643,333. Common shares outstanding rose to 21,666,610 from 18,733,277 at year-end.
- At June 30, approximately $1.3 million remained available under the IPCAVD grant and $452,000 under a clade C grant. A further NIH SBIR award of approximately $277,000 was announced July 31, 2013. The company’s authorized common shares increased to 75 million effective August 1.
Outlook, risks, and contingencies
- Management expected existing cash and remaining NIH grant funds to support planned operations into the first quarter of 2014, and anticipated raising additional capital during 2013. There is no assurance that financing or grant support will be available on acceptable terms or at all; a shortfall could force operations to be reduced, terminated, or combined with another company.
- Management expected ongoing losses and rising R&D costs as clinical programs advance. It anticipated a preventive-vaccine Phase 2 trial could begin in 2014, but trial design and NIH/HVTN support were not yet assured.
- GeoVax funds its ongoing Phase 1 therapeutic trial itself. IMPAACT had advised it could not support a proposed trial in HIV-positive young adults, leaving the company to seek other funding.
- Clinical, regulatory, manufacturing, enrollment, and financing risks could delay or prevent development and commercialization. The company stated it had no approved products and might never generate significant product revenue.
- Outstanding vendor and subcontractor purchase commitments were approximately $201,000, expected to be due in 2013; future minimum lease payments were $62,900 for the remainder of 2013 and $128,920 in 2014. No legal proceedings were reported, and management said there had been no material changes to previously disclosed risk factors.
Key facts for investors to verify
- Cash runway and the timing, amount, and terms of any additional financing.
- Availability and expiration of NIH grant balances, and support for anticipated clinical trials.
- Clinical-trial progress, particularly the proposed preventive Phase 2 trial and the self-funded therapeutic program.
- Potential dilution from warrants, options, preferred stock, and the increased authorized share count.
- Timing and magnitude of future R&D spending, and whether any candidate can achieve regulatory approval and commercialization.